Servier Group

Stories

IDEAYA Biosciences raises $324 million as lead cancer drug nears FDA filing

As of June 2026: Darovasertib development partner

IDEAYA Biosciences closed a $323.6 million stock sale on June 10, 2026. The cash lands as the company prepares to file its first drug with the U.S. Food and Drug Administration (FDA).

Updated Jun 10

Servier spends $2.5 billion on Day One Biopharmaceuticals to lock in a rare pediatric cancer treatment

Money Moves

As of May 2026: Acquirer; expanding rare oncology portfolio

For decades, children with relapsed brain tumors had no approved targeted treatment. That changed in April 2024 when the FDA cleared Ojemda, a once-weekly pill for pediatric low-grade glioma, the most common childhood brain cancer. Day One Biopharmaceuticals, the company behind it, has agreed to be acquired by France's Servier for $2.5 billion in cash—a 68% premium over its previous closing share price.

Updated May 30